Please login to the form below

Not currently logged in
Email:
Password:

NICE rejects head and neck cancer treatment

NICE has published guidance on cetuximab for the treatment of recurrent and/or metastatic squamous cell cancer of the head and neck

The UK National Institute for Health and Clinical Excellence (NICE) has published guidance on cetuximab for the treatment of recurrent and/or metastatic squamous cell cancer of the head and neck. The guidance does not recommend it as a treatment option for patients with this type of cancer.

Squamous cell cancer of the head and neck is cancer of the epithelium (lining cells) of the mouth, nose, throat and surrounding areas.

People currently receiving cetuximab in combination with platinum-based chemotherapy for the treatment of recurrent and/or metastatic squamous cell cancer of the head and neck should have the option to continue treatment until they and their clinician consider it appropriate to stop.

Andrew Dillon, NICE chief executive, said: "When reaching today's decision, the appraisal committee took account of all of the available evidence on the use of cetuximab, in combination with platinum-based chemotherapy, when compared to the existing treatment options already available to patients with metastatic squamous cell head and neck cancer. The committee noted the existing uncertainty over the clinical effectiveness of the treatment and the costs of the treatment when compared to those currently available. The manufacturer's cost-effectiveness analysis resulted in the cost of an additional 'quality adjusted life year' from treatment with cetuximab plus platinum-based chemotherapy compared with platinum-based chemotherapy alone to be £121,367, with a predicted gain in overall survival of just over two months. This would mean the NHS making significant funds available for a very expensive treatment, which may or may not benefit individual patients. Those funds would not then be available for treating other conditions with greater and more certain benefits for other patients.

"The committee also took into account the supplementary advice provided by NICE to be taken into account when appraising treatments at the end of life. The committee noted that cetuximab was used for a small population with a short life-expectancy for a devastating disorder but it did not offer sufficiently greater benefits to these patients compared to existing treatments."

24th June 2009

From: Healthcare

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics